Généralités

Select a topic (

) of interest

• NEW --- COVID-19 vaccines
• UPDATED --- Management of small renal masses
• Second-line therapy in metastatic ccRCC
• Local therapy for mRCC
• First-line systemic therapy in mRCC
• Systemic therapy for HER2-positive early breast cancer
• UPDATE --- CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
• UPDATED --- Radiotherapy for early breast cancer
• Systemic therapy for early stage triple-negative breast cancer
• Brain metastases in patients with HER2+ breast cancer
• NEW --- Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
• NEW --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
• NEW --- Adjuvant treatment approaches for MIBC
• NEW --- Treatment of acute COVID-19
• NEW --- Acute COVID-19 in special populations
• NEW --- Long COVID
• Prise en charge initiale de la douleur due à l’arthrose
• Arthrose : quelles options envisager après l'échec thérapeutique ?
• Prise en charge de la douleur associée à l'arthrose chez les patients atteints de comorbidités
• Orientation et suivi de la douleur chronique associée à l’arthrose
• High-risk non-metastatic prostate cancer
• Tailoring treatment for metastatic hormone-sensitive prostate cancer
• Finding the right ADT for the right patient
• Initial management of nocturia
• High-risk non-metastatic prostate cancer: the devil is in the details
• Tailoring treatment for metastatic hormone-sensitive prostate cancer
• Oligometastatic PCa: treating the primary and/or metastases
• Biochemical recurrence after radical prostatectomy
• CRPC: treatment in daily clinical practice
• mCRPC: novel and emerging agents
• Treatment of low and intermediate-risk PCa
• Active surveillance: yes or no?
• Adverse pathology at radical prostatectomy
• UPDATED --- Finding the right ADT for the right patient
• Management of non-neurogenic female OAB
• Treatment of high-risk PCa: the basics
• Male LUTS: keep on learning
• Challenges in high-risk NMIBC
• Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
• Follow-up surveillance regimes for low-/intermediate-risk NMIBC
• Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
• Initial treatment of MIBC
• New hope for patients progressing after prior treatment for mUCa
• Immunotherapy and antibody-drug conjugates: handling AEs and special populations
• UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa
• UPDATED --- Histological subtypes of (N)MIBC: managed differently compared to pure UCa?